论文部分内容阅读
美国ＦＤＡ心血管和肾药顾问委员会以 7∶1的投票决定 :拒绝布迈 施贵宝 (Ｂｒｉｓｔｏｌ ＭｙｅｒｓＳｑｕｉｂｂ ,ＢＭＳ)公司的普伐他汀 (40ｍｇ)与阿司匹林 (81ｍｇ或32 5ｍｇ)的复方制剂。该公司准备申请用这两个药长期治疗那些具有临床体征明显的心脏病病人 ,以降低死亡
The FDA’s Cardiovascular and Nephrology Advisory Committee voted in a 7: 1: Denial of a combination of pravastatin (40 mg) and aspirin (81 mg or 325 mg) by Bristol Myers Squibb (BMS). The company is ready to apply long-term treatment of these two drugs with those with clinical signs of significant heart disease patients to reduce death